Ascletis Announces Initiation of Two Phase I Studies in U.S. for the Treatment of Obesity: ASC36 Once-Monthly Injection, an Amylin Receptor Peptide Agonist, and ASC36_35FDC Once-Monthly Injection, a Co-Formulation of ASC36 and GLP-1R/GIPR Peptide Agonist ASC35
Source: PRNewswire· August 10, 2026
SynaBot summary
Ascletis has launched two Phase I clinical trials in the U.S. for new obesity treatments. One involves ASC36, an amylin receptor agonist, and the other is ASC36_35FDC, a combination therapy targeting amylin, GLP-1, and GIP receptors.
Key takeaways
- New obesity drug candidates enter U.S. clinical trials.
- One drug targets amylin receptors.
- A combination therapy targets amylin, GLP-1, and GIP.
- Monthly injections are being tested.
Why it matters
These trials explore novel drug combinations for obesity management, potentially offering new tools for individuals seeking weight loss solutions. Success could lead to advanced therapeutic options integrated into health and wellness AI applications.
This story was reported by PRNewswire. Read the full original article:
Read on PRNewswire Try this on SynaBot
Related AI assistants, prompts, and tools from the SynaBot catalog.
